Tarsons Products Limited — PPTs, 23-05-2026: Investor Presentation

**Business Performance:** Tarsons Products reported a consolidated revenue growth of 8% YoY, reaching ₹422.5 Cr in FY26. Domestic sales showed strength, growing 7% for the year (12% in Q4FY26), outperforming industry trends. Export revenue saw a 13% dip in Q4 due to geopolitical issues in the Middle East but concluded FY26 up 3%. The Nerbe acquisition contributed a 14% growth. While reported PAT for FY26 declined 48% to ₹15.5 Cr, mainly due to increased depreciation and finance costs from new facilities, Adjusted Cash PAT demonstrated robust 21% growth, hitting ₹112 Cr. Margins were affected by rising raw material prices and expenses for new facility ramp-up.

**Growth Drivers & Strategy:** The company is strategically investing in future expansion, with new manufacturing facilities at Panchla and Amta commencing commercial supplies and expected to be fully operational by H1FY27. This capacity boost, coupled with an expanded product portfolio including the new cell culture segment, aims to drive accelerated growth by attracting new customers, strengthening existing relationships, and scaling export operations. Management is committed to long-term investments to ensure sustainable growth over the next 3-5 years.

**Recent Developments:** Notable updates include the start of commercial supplies from the Panchla and Amta facilities. Tarsons is also actively expanding its product range by venturing into the cell culture segment and has bolstered its international presence through the acquisition of the European distributor, Nerbe.